What is MOTS-c?

MOTS-c is encoded within the mitochondrial 12S rRNA region and is one of the best-known mitochondria-derived peptides. Its discovery helped expand the view of mitochondria from power generators to signaling organelles that can send peptide messages to the nucleus and other tissues. [1][6]

The core research theme is metabolic stress adaptation. MOTS-c has been linked with AMPK activation, nuclear gene-expression changes under stress, glucose handling, muscle metabolism, and exercise-related signaling in preclinical and human-association literature. [5][16][10]

Naming is inconsistent across sources: MOTS-c, MOTs-C, and mitochondrial ORF of the 12S rRNA type-c usually refer to the same 16-amino-acid mitochondrial peptide. The mitochondrial origin matters because the peptide is framed as a signaling message from mitochondrial DNA, not a conventional nuclear-encoded hormone. [1][6]

What MOTS-c is investigated for

MOTS-c evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Insulin sensitivity and metabolic health

Injectable

52% Emerging

MOTS-c is a metabolic-homeostasis candidate with a recruiting prediabetes and overweight trial; efficacy cannot be inferred until interventional results are posted. [46][1]

Human evidence

A Phase 2 trial is recruiting adults with prediabetes and overweight or obesity, but no outcome results are posted. [46][1]

Animal / mechanistic evidence

Preclinical work supports metabolic homeostasis and insulin-resistance biology. [46][1]

Mitochondrial stress adaptation

Injectable

44% Preliminary

Mitochondrial stress-adaptation support is meaningful mechanistically, while clinical translation remains early. [5][6]

Human evidence

Human clinical meaning is not settled, but the pathway is relevant to metabolic-stress research. [5][6]

Animal / mechanistic evidence

MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress. [5][6]

Exercise adaptation and muscle metabolism

Injectable

32% Limited

Exercise-mimetic claims should remain mechanism and model based until exogenous MOTS-c performance trials report outcomes. [16][10]

Human evidence

Controlled human performance outcomes with exogenous MOTS-c have not been established. [12][16]

Animal / mechanistic evidence

Reviews and preclinical studies link MOTS-c with exercise, mitohormesis, muscle-atrophy signaling, and skeletal-muscle mitochondrial bioenergetics. [10][41]

Cardiovascular risk reduction

Injectable

30% Limited

Cardiovascular benefit remains a biomarker and preclinical hypothesis, not an established prevention or treatment claim. [27][17]

Human evidence

Human cardiovascular evidence is limited to observational biomarker and risk-prediction studies rather than MOTS-c treatment trials. [27][30]

Animal / mechanistic evidence

Animal and tissue studies report myocardial-performance, heart-failure, and diabetic-heart signals tied to MOTS-c biology. [14][17][34]

Longevity and age-related decline

Injectable

24% Limited

Longevity positioning should stay mechanistic; the current evidence does not establish MOTS-c as an anti-aging treatment. [9][18]

Human evidence

No controlled human trial shows that exogenous MOTS-c slows aging or improves longevity outcomes. [18][20]

Animal / mechanistic evidence

Mouse and review literature links MOTS-c to age-dependent physical decline, stress-response biology, and age-related disease mechanisms. [9][18][20]

Evidence snapshot

Overall confidence

Preliminary

45%

MOTS-c has a credible mitochondrial-signaling rationale and active Phase 2a trial context. Practical confidence remains preliminary until controlled human outcome results are available. [1][16][46]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

38%

Human evidence

Preliminary

Published human work is mostly association and trial activity rather than posted efficacy outcomes. The Phase 2a metabolic trial is a translation signal, not proof of benefit. [46][16]

48%

Animal / preclinical

Preliminary

Animal and cell studies repeatedly support metabolic homeostasis, insulin resistance, muscle signaling, and stress-response biology. Translation to user-facing outcomes remains the limiting step. [1][10]

66%

Mechanism support

Moderate

Mitochondrial-to-nuclear signaling and AMPK-linked stress responses give MOTS-c a strong mechanistic frame. Mechanism strength does not replace human outcome data. [5][6]

Forms & administration

MOTS-c is mainly discussed as an injectable research-market protocol. Common practical patterns use morning or pre-workout dosing with an 8-12 week metabolic reassessment window. [16][46]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocol patterns use 5-10 mg per dose. [46]

Frequency

Daily scheduling is the cleanest app pattern for common use. Less frequent schedules are individualized variations. [16]

Timing Considerations

Morning or pre-workout timing is commonly used because the peptide is framed around metabolic energy and exercise adaptation. [16]

Cycle Length

Common cycles use 8-12 week reassessment windows for weight, waist, fasting glucose, lipids, training notes, and tolerability. [46]

What to expect

Weeks 1-2

Injectable metabolic use may show up first as changes in energy, training tolerance, appetite, or sleep, while body-composition and lab shifts remain slower. [16]

Weeks 4-8

Waist, weight trend, fasting glucose, and training capacity become more meaningful when diet and activity stay consistent. [46]

Weeks 8-12

A full cycle may show whether metabolic markers, body-composition trend, or subjective performance moved together rather than as isolated day-to-day noise. [1][46]

After stopping

Energy and training changes may fade toward baseline after the cycle, while metabolic markers need a later comparison to show whether any change held. [1][46]

Safety profile

Injectable MOTS-c safety is mainly a local-injection, product-quality, immune-response, and metabolic-context question. Long-term mitochondrial-signaling exposure and durable metabolic effects remain unresolved. [42][44][46]

Common side effects

Injection-site pain or swelling [45]

Cautions

Unapproved injectable quality [45]
Metabolic disease context [46][16]

What we don't know

Chronic human safety, immunogenicity, and durable metabolic effects are not established. [16][46]

Who MOTS-c is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding
Avoid because reproductive and developmental safety have not been established. [46]
Active cancer or complex metabolic disease
Specialist review is warranted because mitochondrial and metabolic signaling can be disease-context dependent. [16]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Glucose-lowering medications
Glucose-lowering medications can make glucose and insulin-sensitivity changes harder to interpret during injectable MOTS-c use; this is a theoretical metabolic caution. [46]

Pairing notes

Commonly included in these stacks

NAD+ / MOTS-c / 5-Amino-1MQ

NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. NAD+ support targets redox and energy pools, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism.

NAD+MOTS-c5-Amino-1MQ

Regulatory status

United States

MOTS-c has no FDA-approved injectable human use as of 2026-06-21. Its separate 503A question is pending FDA PCAC discussion on July 23, 2026; that process does not establish approval, safety, or effectiveness. [42][44]

Route	FDA drug approval	503A compounding
Injectable	Not Approved As of 2026-06-21, MOTS-c was not FDA-approved as an injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [42][44][45]	Under Review MOTS-c-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [42][44][45]

Injectable

FDA drug approval

Not Approved

As of 2026-06-21, MOTS-c was not FDA-approved as an injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [42][44][45]

503A compounding

Under Review

MOTS-c-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [42][44][45]

International

EU/Europe, UK, Canada, and Australia should be checked by local product and claim; no approved therapeutic MOTS-c product was found in the reviewed official sources.

Sports & competition

WADA's 2026 Prohibited List does not specifically name MOTS-c, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review. [47]

How it works

MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. Its core mechanism is mitonuclear signaling: under metabolic stress, MOTS-c can move into the nucleus and influence gene programs tied to AMPK activity, glucose handling, and cellular stress adaptation. [1][5][6]

That biology makes injectable MOTS-c plausible for metabolic and exercise-adaptation research, but the mechanism is not the same as proven insulin-sensitivity, endurance, or longevity benefit. Human trials still need to show whether systemic exposure produces meaningful outcomes rather than only stress-response signals. [1][16][46]

Research gaps & open questions

What the current literature has not yet settled about MOTS-c:

Posted Phase 2 insulin-sensitivity results would materially change human-evidence confidence. [46]

Human dose-response, pharmacokinetics, and safety monitoring need to be separated from research-market protocol patterns. [16]

Exercise-performance claims need controlled human endpoints rather than mechanism-only extrapolation. [10][16]

Common questions

What is MOTS-c best known for?

MOTS-c is best known as a mitochondrial-derived peptide studied for metabolic stress signaling, insulin-sensitivity biology, and exercise-adaptation pathways. [1][16]

Is MOTS-c proven for weight loss?

No. Injectable MOTS-c has metabolic rationale and active human trial activity, but posted controlled human weight-loss outcomes are not established. [46]

Is MOTS-c FDA-approved?

No. MOTS-c has no FDA-approved injectable human use, and the July 23, 2026 PCAC discussion is a 503A compounding review, not approval. [42][44]

Myths & misconceptions

Myth

MOTS-c is a proven exercise mimetic in humans.

Reality

The exercise-mimetic idea comes from mechanism and preclinical biology; human performance outcomes remain unproven. [16]

Myth

A recruiting MOTS-c trial proves it works.

Reality

A recruiting trial shows research activity, not benefit. Results need to be posted or published before raising confidence. [46]

History & discovery

MOTS-c was introduced as a mitochondrial-derived peptide encoded by the 12S rRNA region, turning mitochondrial DNA from a genome of energy machinery into a source of signaling peptides. [1][6]

The original Cell Metabolism paper linked MOTS-c to metabolic homeostasis, obesity resistance, and insulin sensitivity in cell and mouse models. [1]

Follow-up work showed MOTS-c can move to the nucleus during metabolic stress and regulate nuclear gene expression, broadening interest beyond simple mitochondrial biology. [5][6]

A Phase 2 trial is recruiting adults with prediabetes and overweight or obesity, marking active clinical translation without posted efficacy outcomes. [46]

Published research 47 studies

[1]

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.

Cell metabolism, 2015 Mar 3. in vitro.

[2]

MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.

Free radical biology & medicine, 2016 Nov. review.

[3]

Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2018 Aug. review.

[4]

Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance.

Pediatric diabetes, 2018 Apr 25. review.

[5]

The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.

Cell metabolism, 2018 Sep 4. in vitro.

[6]

MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus.

BioEssays : news and reviews in molecular, cellular and developmental biology, 2019 Sep. review.

[7]

β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease.

Journal of thrombosis and thrombolysis, 2020 Apr. human clinical.

[8]

A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.

Aging, 2021 Jan 19. review.

[9]

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.

Nature communications, 2021 Jan 20. review.

[10]

MOTS-c reduces myostatin and muscle atrophy signaling.

American journal of physiology. Endocrinology and metabolism, 2021 Apr 1. review.

[11]

MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway.

Biochimica et biophysica acta. Molecular basis of disease, 2021 Jun 1. animal.

[12]

Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.

Journal of applied physiology (Bethesda, Md. : 1985), 2021 Sep 1. human clinical.

[13]

Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.

Scientific reports, 2021 Aug 19. human clinical.

[14]

The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats.

Scientific reports, 2021 Oct 11. animal.

[15]

[Effects of exercise intervention on mitochondrial-derived peptide MOTS-c in the germ cells of obese men].

Zhonghua nan ke xue = National journal of andrology, 2021 Jun. review.

[16]

Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c).

Diabetes & metabolism journal, 2022 May. review.

[17]

Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice.

Journal of cellular and molecular medicine, 2022 Nov. animal.

[18]

MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.

International journal of molecular sciences, 2022 Oct 9. review.

[19]

Circulating levels of MOTS-c in patients with breast cancer treated with metformin.

Aging, 2022 Dec 6. human clinical.

[20]

Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging.

Journal of translational medicine, 2023 Jan 20. review.

[21]

MOTS-c Functionally Prevents Metabolic Disorders.

Metabolites, 2023 Jan 13. review.

[22]

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

Frontiers in endocrinology, 2023. review.

[23]

Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.

Diabetes & metabolism journal, 2023 May. review.

[24]

Role of MOTS-c in the regulation of bone metabolism.

Frontiers in physiology, 2023. review.

[25]

MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria.

Mitochondrion, 2023 Jul. review.

[26]

Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer.

Current radiopharmaceuticals, 2024. review.

[27]

The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study.

Blood purification, 2024. human clinical.

[28]

MOTS-c Impact on Muscle Cell Differentiation and Metabolism Across Fiber Types.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2025 Jan 21. in vitro.

[29]

MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study.

Medicina (Kaunas, Lithuania), 2025 Feb 12. review.

[30]

Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.

Biologics : targets & therapy, 2025. review.

[31]

MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.

Redox biology, 2025 Jul. review.

[32]

MOTS-c-modified functional self-assembly peptide hydrogels enhance the activity of nucleus pulposus-derived mesenchymal stem cells of intervertebral disc degeneration.

Materials today. Bio, 2025 Jun. in vitro.

[33]

Mitochondria-derived peptide MOTS-c and its role in OSA pathogenesis: a potential therapeutic target?

Sleep and biological rhythms, 2025 Jul. review.

[34]

Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.

Frontiers in physiology, 2025. review.

[35]

Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.

Medicine and science in sports and exercise, 2025 Dec 1. human clinical.

[36]

A mitochondrial-derived peptide MOTS-c contributes to the protective effect against brain injury associated with LPS-induced sepsis by strengthening the blood-brain barrier's ultrastructure.

The International journal of neuroscience, 2026 Mar. review.

[37]

Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.

Experimental & molecular medicine, 2025 Aug. in vitro.

[38]

MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction.

Archives of endocrinology and metabolism, 2025 Sep 26. review.

[39]

MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism.

Free radical biology & medicine, 2025 Dec 16. review.

[40]

MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment.

Life sciences, 2025 Dec 1. review.

[41]

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.

Free radical biology & medicine, 2026 Mar 16. review.

[42]

Drugs@FDA/openFDA query for MOTS-c

U.S. Food and Drug Administration / openFDA. database query.

[43]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration, 2026-05-14. regulatory.

[44]

July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee

U.S. Food and Drug Administration, 2026-04-16. regulatory.

[45]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[46]

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

ClinicalTrials.gov. clinical trial registry.

[47]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency, 2026. regulatory.